| 1. |
Toyoshima T, Kumamaru W, Hayashida J, Moriyama M, Kitamura R, Tanaka H, Yamada A, Itoh K, Nakamura S. In vitro induction of specific CD8+ T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma. Cancer Lett. 2012 Sep 1;322(1):86-91. doi: 10.1016/j.canlet.2012.02.016. Epub 2012 Feb 22. |
2. |
Yamada A, Sasada T, Noguchi M, Itoh K. The next generation of peptide vaccines for advanced cancer. Cancer Sci. 2012 Oct 27. doi: 10.1111/cas.12050. [Epub ahead of print] |
| 3. |
Sasada T, Noguchi M, Yamada A, Itoh K. Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother. 2012 Sep 1;8(9). [Epub ahead of print] |
| 4. |
Okuno K, Sugiura F, Itoh K, Yoshida K, Tsunoda T, Nakamura Y: Recent advances in active specific cancer vaccine treatment for colorectal cancer. Current Pharmaceutical Biotechnology 13, 1439-1445, 2012. |
| 5. |
Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Takashi Mine, Tetsuya Ioji, Kyogo Itoh, Kazuo Shirouzu, Tetsuro Sasada and Shinzo Takamori. Personalized peptide vaccination in patients with refractory non-small cell lung cancer, Int J Oncol, 40: 1492-1500, 2012. |
| 6. |
Terazaki Y, Yoshiyama K, Matsueda S, Watanabe N, Kawahara A, Naito Y, Suekane S, Komatsu N, Ioji T, Yamada A, Mine T, Terasaki M, Itoh K, Takamori S, Sasada T. Immunological Evaluation of Personalized Peptide Vaccination in Refractory Small Cell Lung Cancer. Cancer Sci, 2012 Apr;103(4):638-44. doi: 10.1111/j.1349-7006.2012.02202.x. Epub 2012 Feb 13. |
| 7. |
Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status, and pre-existing antigen -specific immunity as possible biomarkers for patient prognosis. Experimental and Therapeutic Medicine, 3: 463-469, 2012. |
| 8. |
Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Yamada A, Doi A, Suekane S, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer. 2012 Jun 15;118(12):3208-21. doi: 10.1002/cncr.26636. Epub 2011 Nov 9. |
| 9. |
Sasada T, Suekane S. Variation of Tumor-Infiltrating Lymphocytes in Human Cancers: Controversy on Clinical Significance. Immunotherapy, 2011 Oct;3(10):1235-51. |
| 10. |
Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, Sasada T, Yamada A, Itoh K. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate. 2012 Jun 1;72(8):834-45. doi: 10.1002/pros.21485. Epub 2011 Sep 19. |
| 11. |
Terasaki M,Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A, Itoh K. A Phase I Trial of Personalized Peptide Vaccine for HLA-A24 Patients with Recurrent or Progressive Glioblastoma Multiforme. J Clin Oncol, 2011 Jan, 29(3):337-44. |
| 12. |
Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int. 2011 Sep;108(6):831-8. doi: 10.1111/j.1464-410X.2010.09933.x. Epub 2010 Dec 16. |
| 13. |
Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K. Phase-I clinical study of a personalized peptide vaccination available for six different HLA (HLA-A2, -A3, -A11, -A24, -A31, and -A33)-positive patients with advanced cancer. Exp Ther Med. 2011, 2: 109-117. |
| 14. |
Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T, Yanagimoto H, Kawano K, Itoh K, Yamada A. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases. Oncol Report. 2011 Jan; 25:57-62. |
| 15. |
Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate. 2011 Apr;71(5):470-9. |
| 16. |
Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther. 2011 Jan 12;10(12):1266-79. |
| 17. |
Komatsu N, Yutani S, Yamada A, Shichijo S, Yoshida K, Itou M, Kuromatsu R, Ide T, Tanaka M, Sata M, and Itoh K. Prophylactic effect of peptide vaccination against hepatocellular carcinoma associated with hepatitis C virus. Experimental and Therapeutic Medicine. 2010; 1(4):619-626. |
| 18. |
Komatsu N, Terasaki Y, Moriya F, Suekane S, Noguchi M, Todo S, Itoh K, and Shichijo S. A β-tubulin 5-derived peptide can induce CTLs restricted to the HLA -A24 allele in prostate cancer patients. Experimental and Therapeutic Medicine. 2010,1：833-839. |
| 19. |
Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int. 2010 Dec 16. doi: 10.1111/j.1464-410X.2010.09933.x. [Epub ahead of print] |
| 20. |
Iseki K, Matsunaga H, Komatsu N, Suekane S, Noguchi M, Itoh K, Yamada A. Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. Cancer Sci. 2010 Oct;101(10):2110-4. doi: 10.1111/j.1349-7006.2010.01653.x. Epub 2010 Jul 30. |
| 21. |
Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, Tani T, Yamada A, Kwon A, Komatsu N, Itoh K, Noguchi M. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncology Reports 2010, 24:795-801. |
| 22. |
Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother. 2010 Jul;59(7):1001-9. Epub 2010 Feb 10. |
| 23. |
Uemura H, Fujimoto K, Mine T, Uejima S, De Velasco MA, Hirao Y, Komatsu N, Yamada A, Itoh K. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Sci 2010, 101:601-608 |
